<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591019</url>
  </required_header>
  <id_info>
    <org_study_id># 65171</org_study_id>
    <nct_id>NCT00591019</nct_id>
  </id_info>
  <brief_title>Use of Modafinil in the Treatment of Tinnitus</brief_title>
  <official_title>Use of Modafinil in the Treatment of Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study on the effects of the FDA approved drug Modafinil upon attention problems associated
      with tinnitus. This is considered to be a safe drug with few side effects. Each subject will
      be asked to participate in 3 sessions each lasting approximately 1 hour in which cognitive
      testing and recordings will be taken. The study involves each subject taking a 2- week supply
      of Modafinil and a 2- week supply of placebo. We hypothesize inattention related to
      thalamocortical dysrhythmia found in tinnitus can be reduced by Modafinil thus improving
      vigilance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modafinil, a drug primarily used in the treatment for narcolepsy, is also being using in
      treating attention problems found in Attention Deficit Hyperactive Disorder (ADHD). This
      study will investigate the efficacy of Modafinil upon attention deficits found in tinnitus
      patients by assessing pre-attentional and attentional processes (e.g., the amplitude of
      auditory evoked responses and simple reaction time).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early due to lack of change in primary and secondary outcome measures.
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The P50 Amplitude (i.e. Evoked Auditory Response Potential Recorded in Millivolts 50 Milliseconds After Sound Onset).</measure>
    <time_frame>5 weeks</time_frame>
    <description>P50 is an auditory evoked response potential sensitive to states of arousal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Simple Reaction Time (Attention)for Baseline, Modafinil and Placebo Arms.</measure>
    <time_frame>5 weeks</time_frame>
    <description>Simple reaction time to an auditory signal is a measure of attention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>modafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>200 mg/day, morning dose</description>
    <arm_group_label>modafinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill once per day in the morning.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of tinnitus should be established by subject through exam and history
             performed by study physician in Ear, Nose and Throat (ENT) clinic.

          -  Subjects will be age 20 or older.

          -  Subjects should have tinnitus symptoms severe enough to seek medical attention.

          -  Subjects will have been seen in the Hearing and Balance Center at University of
             Arkansas for Medical Sciences (UAMS).

          -  Subjects will have had an audiogram.

          -  Signed informed consent.

          -  Women of childbearing potential must have a negative pregnancy test at screening and
             before being prescribed the study drug.

          -  Peripheral neuropathy.

          -  Hematologic (minimal values) at screening Absolute neutrophil count &gt; 1,500 mm^3
             Hemoglobin &gt; 8.0 g/dl Platelet count &gt; 100,000 mm^3

        Exclusion Criteria:

        Disease-Specific Concerns

          -  Subjects who have locally advanced breast cancer with skin ulceration will be excluded
             from this study due to the risk of worsening ulcers and healing difficulties

          -  Stage IV breast cancer

          -  Inflammatory breast cancer

        General Medical Concerns

          -  Subjects with Echo Cardiogram performance status 2, 3, and 4 are not eligible for this
             study

          -  Allergy to any component of the treatment regimen

          -  Women who are breast feeding

          -  Pregnancy or refusal to use effective contraception while participating in this study

          -  Inability to comply with study and/or follow-up procedures

          -  Subjects with secondary malignancy other than superficial skin cancer (squamous cell
             carcinoma and basal cell carcinoma of the skin) should be excluded

        Bevacizumab-Specific Concerns

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study

          -  Blood pressure of &gt; 150/100 mmHg. Essential hypertension well controlled with anti
             hypertensive is not an exclusion criterion

          -  Unstable angina

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see
             Appendix D)

          -  History of myocardial infarction within 6 months

          -  History of stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Presence of central nervous system or brain metastases

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, anticipation of need for major surgical procedure during the course of
             the study

          -  Minor surgical procedures such as fine needle aspirations or core biopsies within 7
             days prior to Day 0

          -  Pregnant (positive pregnancy test) or lactating

          -  Urine protein: creatinine ratio &gt;1.0 at screening

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 0

          -  Serious, non-healing wound, ulcer, or bone fracture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Dornhoffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>February 28, 2011</results_first_submitted>
  <results_first_submitted_qc>April 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2011</results_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P50, Psychomotor Vigilance Test (PVT), Arousal, Reaction Time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from treatment clinic, seeking treatment for tinnitus.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Baseline, Modafinil 200 mg/Day, Placebo</title>
          <description>Subjects are tested at baseline, then after Modafinil (200mg/day, a.m. administration) for 14 days, then after placebo (for 14 days).</description>
        </group>
        <group group_id="P2">
          <title>Baseline, Placebo, Modafinil 200 mg/Day</title>
          <description>Subjects are tested after baseline, then after taking a sugar pill once per day in the morning for 14 days, and then after taking modafinil 200 mg/day for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 1 (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">One subject dropped out after baseline</participants>
                <participants group_id="P2" count="3">One subject dropped out after baseline</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intevention 2 (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Subjects were tested at baseline, then entered either the modafinil or placebo condtion and then the remaining condition.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The P50 Amplitude (i.e. Evoked Auditory Response Potential Recorded in Millivolts 50 Milliseconds After Sound Onset).</title>
        <description>P50 is an auditory evoked response potential sensitive to states of arousal.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Testing.</title>
            <description>Establish baseline levels of performance</description>
          </group>
          <group group_id="O2">
            <title>Modafinil</title>
            <description>Subjects are tested after taking Modafinil (200mg/day, a.m. administration) for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects are tested after taking a sugar pill once per day in the morning for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The P50 Amplitude (i.e. Evoked Auditory Response Potential Recorded in Millivolts 50 Milliseconds After Sound Onset).</title>
          <description>P50 is an auditory evoked response potential sensitive to states of arousal.</description>
          <units>milli volts</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread=".15"/>
                    <measurement group_id="O2" value="1.47" spread=".28"/>
                    <measurement group_id="O3" value="1.23" spread=".26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simple Reaction Time (Attention)for Baseline, Modafinil and Placebo Arms.</title>
        <description>Simple reaction time to an auditory signal is a measure of attention.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Testing.</title>
            <description>Establish baseline levels of performance</description>
          </group>
          <group group_id="O2">
            <title>Modafinil</title>
            <description>Subjects are tested after taking Modafinil (200mg/day, a.m. administration) for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects are tested after taking a sugar pill once per day in the morning for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Simple Reaction Time (Attention)for Baseline, Modafinil and Placebo Arms.</title>
          <description>Simple reaction time to an auditory signal is a measure of attention.</description>
          <units>milli seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.80" spread="12.64"/>
                    <measurement group_id="O2" value="268.12" spread="14.41"/>
                    <measurement group_id="O3" value="247.11" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Baseline Testing.</title>
          <description>Establish baseline levels of performance</description>
        </group>
        <group group_id="E2">
          <title>Modafinil</title>
          <description>Subjects are tested after taking Modafinil (200mg/day, a.m. administration) for 14 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subjects are tested after taking a sugar pill once per day in the morning for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to lack of change in primary and secondary outcome measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr John Dornhoffer</name_or_title>
      <organization>University of Arkansas for Medical Sciences (UAMS)</organization>
      <phone>501 686-5140</phone>
      <email>dornhofferjohnl@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

